Dennis R. Benjamin

Seagen (United States) — United States

Medicine · Health Sciences

21h-index3.8kcitations95works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(61), HER2/EGFR in Cancer Research(56), Glycosylation and Glycoproteins Research(14), Cell Adhesion Molecules Research(12), CAR-T cell therapy research(10)

Publications95 total

Data from SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
2023Open Access
Data from Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody–Drug Conjugate Via Fc–FcγR Interaction
2023Open Access
Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
2023Open Access
Data from SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
2023Open Access
Data from Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates
2023Open Access
Supplementary Table 1 from SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
2023Open Access
Data from Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates
2023Open Access
Data from Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody–Drug Conjugate Via Fc–FcγR Interaction
2023Open Access
Figure S1-S4 from Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
2023Open Access
Figure S1 and antibody sequence from Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody–Drug Conjugate Via Fc–FcγR Interaction
2023Open Access
Supplementary Figures from Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates
2023Open Access
Figure S1 and antibody sequence from Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody–Drug Conjugate Via Fc–FcγR Interaction
2023Open Access
Supplementary Figure Legends from Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates
2023Open Access
Supplementary Table 1 from SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
2023Open Access
Data from Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
2023Open Access
Data from Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
2023Open Access
Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
2023Open Access
Supplementary Figure Legends from Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates
2023Open Access
Supplementary Figures from Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates
2023Open Access
Figure S1-S4 from Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Nicole M. Okeley(14), Peter D. Senter(14), Lori Westendorf(14), Martha E. Anderson(14), Stephen C. Alley(12), Django Sussman(12), Che‐Leung Law(12), Jamie B. Miyamoto(11), Xinqun Zhang(10), Changpu Yu(10), Maureen C. Ryan(10), Robert P. Lyon(9), Mechthild Jonas(9), Heather Kostner(8), Scott C. Jeffrey(7), Ivan J. Stone(7), Weiping Zeng(7), Kerry Klussman(6), Kim K. Emmerton(6), Michelle Ulrich(6)